Staphylococcus aureus bacteraemia
S. aureus growing in a blood culture is never a lab accident. It seeds heart valves, spine and joints, and 15–40% of patients die in hospital.
What it is
Growth of Staphylococcus aureus (methicillin-susceptible, MSSA, or methicillin-resistant, MRSA) in one or more blood cultures. It is always treated as a true infection, because the organism spreads from the blood to heart valves, bones, joints and implanted devices.
Who gets it
One of the commonest causes of bloodstream infection in hospital and in the community, with in-hospital mortality reported between about 15% and 40%. Intravascular catheters and skin and soft-tissue infections are the most frequent sources; endocarditis is found in about 10–20% of patients.
Causes
- Intravascular catheters (central and peripheral lines, haemodialysis catheters): the most frequent source
- Skin and soft-tissue infection, surgical-site infection and wounds
- Bone and joint infection, pneumonia and urinary tract (a S. aureus urine culture can be a sign of bacteraemia)
- Injection drug use
- No source found (community onset without a clear focus), which raises the chance of endocarditis or a deep focus
Risk factors
- Central venous catheters, haemodialysis and recent surgery
- Prosthetic heart valves, pacemakers and defibrillators, prosthetic joints and other implants
- Injection drug use
- Diabetes, cancer, immunosuppression and chronic skin disease
- Nasal or skin colonisation with S. aureus, including MRSA
Pathophysiology
A breach (catheter, wound, needle) lets S. aureus into the blood → surface adhesins stick it to damaged endothelium, fibrin and plastic, where it builds a biofilm that antibiotics penetrate poorly → from the blood it seeds distant sites (heart valves, vertebrae and discs, epidural space, joints, prosthetic material), and up to a third of these foci give no clinical sign at first → a source that stays in place (an infected line or device, an undrained abscess) keeps reseeding the blood, so cultures stay positive → persistent bacteraemia means a hidden focus and a higher risk of complications and death → clearing it needs source removal plus a bactericidal drug for long enough to sterilise the deep foci.
Classification
- Uncomplicated: no endocarditis on examination or echocardiography, no implanted prosthetic material, follow-up blood cultures negative early in treatment, fever settling quickly and no deep or metastatic focus
- Complicated: any of endocarditis, implanted prosthetic material, persistent bacteraemia, persistent fever or a deep or metastatic focus (vertebral osteomyelitis, epidural abscess, septic arthritis, abscesses)
- By susceptibility: MSSA or MRSA
- By acquisition: hospital-onset, healthcare-associated or community-onset (community onset carries more hidden foci)
Symptoms and signs
- Fever and rigors, sometimes with sepsis or septic shock
- Redness, pus or pain at a line or wound site, which may be absent
- New back pain (vertebral osteomyelitis or epidural abscess) or a hot swollen joint
- New murmur, heart failure or embolic signs (endocarditis)
- Cough and breathlessness with septic lung emboli in tricuspid endocarditis
Diagnosis
- Clinical
- A positive blood culture with S. aureus is acted on at once, never repeated «to see if it was a contaminant». The bedside search is for the source and for metastatic foci: every line and wound, the spine, joints, heart sounds, skin and nails.
- Tests
- Blood cultures before antibiotics, then follow-up blood cultures from about 1–3 days after starting active therapy and repeated until they are negative; susceptibility testing (MSSA or MRSA, mecA); inflammatory markers and renal function; urine culture. Persistent positivity triggers a fresh search for a focus.
- Imaging
- Echocardiography in every patient: transthoracic first in many centres, with a low threshold for transoesophageal echocardiography (more sensitive) when there is a prosthetic valve or cardiac device, persistent bacteraemia, community onset without a source, injection drug use or a negative transthoracic study despite suspicion. MRI of the spine for back pain; FDG-PET/CT can find hidden foci when cultures stay positive.
Differential diagnosis
- Coagulase-negative staphylococci in one of several bottles, which is often a skin contaminant
- Bacteraemia with streptococci or enterococci (different sources and management)
- Gram-negative bacteraemia from a urinary or abdominal source
- Non-infectious fever (drug fever, venous thrombosis, gout) in a patient with a line
S. aureus in the blood: uncomplicated, complicated or a look-alike?
| Picture | Echo and imaging | Follow-up blood cultures | What it means |
|---|---|---|---|
| Uncomplicated S. aureus bacteraemia | No endocarditis; no implant; no deep focus | Negative early in treatment | Line removed, fever gone quickly; shorter course, length set by the guideline |
| Infective endocarditis | Vegetation, abscess or new regurgitation on echo | Often stay positive | Complicated; prolonged IV therapy and an endocarditis team |
| Vertebral osteomyelitis or epidural abscess | Spine MRI shows the focus | May stay positive | Complicated; drainage when needed and a prolonged course |
| Coagulase-negative staphylococci in one bottle | Not needed for a single contaminant | Usually negative | Often a skin contaminant, unless a line or prosthesis is infected; S. aureus never gets this benefit of the doubt |
Goal of treatment
Sterilise the blood and every focus, remove the source, detect endocarditis and metastatic infection early, and choose the most active drug so that relapse and death are prevented.
Treatment
- Procedure
- Source control as soon as possible: remove infected intravascular catheters and, where feasible, infected devices; drain abscesses. A line in place during the bacteraemia is considered for removal even when another source is suspected.
- Medical
- MSSA: an anti-staphylococcal beta-lactam (such as cefazolin, oxacillin or flucloxacillin) is the definitive treatment; vancomycin is associated with higher mortality in MSSA and is not used as definitive therapy when a beta-lactam can be given. A penicillin allergy label is checked rather than accepted.
- Medical
- MRSA: vancomycin or daptomycin, chosen and monitored with infectious diseases advice.
- Medical
- Duration is set by the guideline: a shorter intravenous course only for strictly uncomplicated bacteraemia, and a prolonged course for complicated disease or when no source is found, counted from the first negative blood culture.
- Follow-up
- Infectious diseases consultation, which observational studies link to lower mortality and to more complete care (repeat cultures, echocardiography, source removal); repeat blood cultures until negative and reassess when they stay positive.
Complications
- Infective endocarditis, including of normal valves
- Vertebral osteomyelitis, discitis and spinal epidural abscess
- Septic arthritis and infection of prosthetic joints
- Septic emboli to lungs, brain, spleen and kidneys
- Persistent bacteraemia and relapse after treatment
- Septic shock and death
Common traps
- One positive bottle of S. aureus may be a contaminant: S. aureus is almost never a contaminant, so every positive culture is treated and investigated
- The line is out and the patient feels better, so a few days of oral antibiotics will do: without echocardiography, negative follow-up cultures and a course of the length the guideline sets, relapse and missed endocarditis are common
- Vancomycin covers MSSA as well, so it is fine to continue it: for MSSA an anti-staphylococcal beta-lactam is more effective, and staying on vancomycin is associated with higher mortality
- A normal transthoracic echo rules out endocarditis: it misses small vegetations and prosthetic-valve disease, so transoesophageal echo is done when the risk is high
- Persistent fever means the antibiotic is wrong: more often there is an undrained focus or a retained line or device, so repeat cultures and search for the source
Prognosis
Mortality remains high. Outcomes are worse with persistent bacteraemia, endocarditis, an unknown or uncontrolled source, older age and MRSA; following the full bundle (source removal, echocardiography, follow-up cultures, the right drug for long enough) improves them.
Prevention
- Central line insertion and maintenance bundles, and removal of lines that are no longer needed
- Hand hygiene and contact precautions for MRSA carriers
- Prompt drainage of skin abscesses and care of wounds
- Harm reduction and sterile injecting equipment for people who inject drugs
Test yourself
Think of the answer, then tap the question to see it.
Why is a single blood culture growing S. aureus never dismissed as contamination, unlike coagulase-negative staphylococci?
Contamination with S. aureus is rare, while true bacteraemia is common and dangerous: it seeds valves, spine and joints and carries high mortality, so it is always treated and investigated.
What are the four fixed steps in managing any S. aureus bacteraemia?
Remove the source (line, device, abscess), perform echocardiography, repeat blood cultures until negative, and give an appropriate bactericidal drug (a beta-lactam for MSSA) for the length the guideline sets.
Which features make an S. aureus bacteraemia complicated rather than uncomplicated?
Endocarditis, implanted prosthetic material, persistent positive cultures, fever that does not settle, or a deep or metastatic focus such as vertebral osteomyelitis or an epidural abscess.
When is transoesophageal rather than only transthoracic echocardiography indicated in S. aureus bacteraemia?
With a prosthetic valve or cardiac device, persistent bacteraemia, community onset without a source, injection drug use, or a negative transthoracic study when suspicion remains.
A man with MSSA bacteraemia from a central line is improving on vancomycin; cultures are now negative. What should change and why?
Switch to an anti-staphylococcal beta-lactam such as cefazolin: it is more effective than vancomycin for MSSA. Make sure the line is out, echocardiography is done and the course length follows the guideline.
Connections
Educational information, not medical advice. For any symptom, see a health professional.
Sources: Management of Staphylococcus aureus Bloodstream Infections (Frontiers in Medicine (open access, PMC), 2021); Redefining Staphylococcus aureus bacteremia: A structured approach guiding diagnostic and therapeutic management (Journal of Infection (PMC), 2023); Infectious Diseases Consultation Lowers Mortality From Staphylococcus aureus Bacteremia (Medicine (Baltimore) (PMC), 2009); Impact of routine bedside infectious disease consultation on clinical management and outcome of Staphylococcus aureus bacteraemia in adults (Clinical Microbiology and Infection (open access, PMC), 2015).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.

